International Journal of Science and Research (IJSR)
ISSN: 2319-7064
SJIF (2022): 7.942

Innovations in Drug Delivery: From Nanoparticles to Biomaterials

Dr Mayur Rasiklal Yadav

Email: yarmayur[at]gmail.com
Independent Researcher

Abstract: ***The field of drug delivery has seen significant advancements, with nanoparticles emerging as a groundbreaking technology. However, these nanoparticle-based systems face challenges such as potential toxicity, limited scalability, and regulatory hurdles. As a response, the focus has been shifting towards biomaterials, such as hydrogels, dendrimers, and biopolymers, which offer unique properties and can interact with biological systems in more predictable and safe ways. This paradigm shift aims to enhance drug delivery efficiency, minimize adverse effects, improve patient compliance, and pave the way for personalized medicine. Biomaterials offer biocompatibility, tunable properties, and multifunctionality, which can be engineered to respond to environmental stimuli, encapsulate a wide range of therapeutic agents, and reduce immunogenicity. Hybrid systems that combine the advantages of nanoparticles and biomaterials create synergistic effects for enhanced drug delivery. The transition from nanoparticles to biomaterials in drug delivery presents numerous benefits, including improved therapies, fewer adverse effects, more patient compliance, enhanced regenerative medicine, smart drug delivery systems, innovative therapeutic modalities, sustainability, and environmental advantages. However, realizing these implications will require ongoing research, collaboration, and careful consideration of ethical and regulatory challenges.***

Keywords: Drug Delivery, Nanoparticles, Hydrogels, Dendrimers, Biopolymers, Biomaterials

1. Introduction

The field of drug delivery has undergone significant advancements over the past few decades, with nanoparticles emerging as a groundbreaking technology. These tiny carriers, often engineered from materials like lipids, polymers, and metals, have shown immense potential in improving the efficacy and targeting of therapeutic agents. Nanoparticles offer numerous advantages, including enhanced solubility, controlled release, and the ability to cross biological barriers. However, despite these promising attributes, the clinical translation of nanoparticle-based drug delivery systems has faced challenges such as potential toxicity, limited scalability, and regulatory hurdles.

In response to these challenges, the focus has been gradually shifting towards biomaterials as an alternative and complementary approach in drug delivery. Biomaterials, which include a diverse range of substances derived from natural or synthetic sources, offer unique properties that can address some of the limitations associated with nanoparticles. These materials are often biocompatible, biodegradable, and can be engineered to interact with biological systems in more predictable and safe manners. Examples of biomaterials include hydrogels, biopolymers, and tissue-engineered scaffolds, each offering distinct advantages for drug delivery applications.

The transition from nanoparticles to biomaterials in drug delivery represents a paradigm shift, emphasizing the integration of biology with materials science to create more effective and patient-friendly therapeutic solutions. This approach not only aims to enhance drug delivery efficiency but also seeks to minimize adverse effects, improve patient compliance, and pave the way for personalized medicine. This introduction sets the stage for a detailed exploration of how biomaterials are being utilized to revolutionize drug delivery systems, their advantages over traditional nanoparticles, and the future prospects of this burgeoning field.

Because nanoparticles may improve medication targeting and delivery efficiency, the area of drug delivery has placed more emphasis on their research in recent years. Drug solubility has been improved, systemic adverse effects have been decreased, and controlled release mechanisms have been made possible thanks in large part to nanoparticles, which include substances like liposomes, dendrimers, and solid lipid nanoparticles. Their tiny size enables special cellular interactions, which is essential for therapies like cancer therapy.

However, despite the potential benefits of using nanoparticles, several drawbacks, including possible toxicity, immunogenicity, and environmental effect, have led to a move toward more environmentally friendly and biocompatible substitutes. The increasing use of biomaterials in medication delivery systems is indicative of this change. Biomaterials are materials that interact more harmoniously with biological processes. They may be obtained from both natural and synthetic sources. They provide improved biocompatibility, less off-target impacts, and biological process mimicking capabilities.



Figure 1: Biomaterials in Drug Delivery (Source: https://www.mdpi.com/1422-0067/25/6/3126)

The shift from nanoparticles to biomaterials is an example of how medication delivery technologies have evolved, with an emphasis on enhancing patient outcomes and being compatible with biological systems. This introduction will explore how this shift tackles the difficulties presented by nanoparticles, the creative ways that biomaterials are being used to deliver drugs, and the promise that these materials have for the development of personalized medicine and other medical therapies in the future.

2. Literature Review

The transition from nanoparticles to biomaterials in drug delivery represents a paradigm shift in the field of therapeutic interventions, underscored by the evolving understanding of material biocompatibility, targeting efficiency, and drug release kinetics. Nanoparticles have historically dominated drug delivery systems due to their ability to enhance solubility, protect drugs from degradation, and provide controlled release profiles (Kumari et al., 2010; Maeda, 2001; Farokhzad and Langer, 2009). However, recent advancements have highlighted significant limitations, including potential toxicity, limited biodegradability, and challenges in large-scale production (Oberdörster et al., 2005; Chithrani et al., 2006; Dobrovolskaia et al., 2008).

Biomaterials, including hydrogels, dendrimers, and biopolymers, offer promising alternatives due to their inherent biocompatibility, tunable properties, and multifunctionality (Peppas et al., 2000; Hubbell, 1995; Duncan and Gaspar, 2011). Hydrogels, for example, can be engineered to respond to environmental stimuli such as pH and temperature, enabling site-specific drug release (Bae et al., 2011; Kost and Langer, 2012). Their high water content and porosity also facilitate the encapsulation of a wide range of therapeutic agents, from small molecules to large proteins and nucleic acids (Li and Mooney, 2016; Nguyen and West, 2002).

Dendrimers, with their highly branched, tree-like structures, offer unique advantages in drug delivery, including precise molecular weight control, high drug loading capacity, and the ability to modify surface functionalities for targeted delivery (Majoros et al., 2008; Kesharwani et al., 2014). Their multivalency allows for simultaneous conjugation of multiple therapeutic agents and targeting ligands, enhancing therapeutic efficacy and reducing off-target effects (Cheng et al., 2008; Menjoge et al., 2010).

Biopolymers, such as chitosan, alginate, and collagen, are derived from natural sources and exhibit excellent biocompatibility and biodegradability (Kumar et al., 2004; Sahoo et al., 2009; Lee et al., 2003). Chitosan, for instance, has been extensively studied for its mucoadhesive properties and ability to open tight junctions, improving drug absorption across mucosal surfaces (Illum, 1998; Mao et al., 2004). Alginate's gelation properties, triggered by ionic crosslinking, make it suitable for encapsulating cells and bioactive molecules, offering potential in tissue engineering and regenerative medicine (Lee and Mooney, 2012; Augst et al., 2006).

The transition to biomaterials also addresses the challenge of immune system evasion, which has plagued many nanoparticle-based systems. Biomaterial-based carriers can be designed to mimic natural extracellular matrices, reducing immunogenicity and improving circulation time (Langer and Tirrell, 2004; Veiseh et al., 2015). Furthermore, the ability to design biomaterials with specific degradation rates aligns with the need for controlled drug release over extended periods, tailored to the therapeutic requirements (Langer and Peppas, 2003; Siepmann and Göpferich, 2001).

Recent studies have demonstrated the potential of hybrid systems that combine the advantages of nanoparticles and biomaterials, creating synergistic effects for enhanced drug delivery (Kamaly et al., 2016; Hrkach et al., 2012). For example, the integration of nanoparticle technology with hydrogel matrices can provide a dual mechanism of drug release, where nanoparticles offer immediate release while the hydrogel ensures sustained delivery (Soni et al., 2016; Zhan et al., 2011). These hybrid systems can be engineered to respond to multiple stimuli, further improving the precision of drug delivery (Ge et al., 2009; Raghupathi et al., 2017).

In summary, the transition from nanoparticles to biomaterials in drug delivery is driven by the need for improved biocompatibility, targeted delivery, and controlled release. Biomaterials offer versatile platforms that can be tailored to specific therapeutic needs, addressing many of the limitations associated with traditional nanoparticle systems. The ongoing development of hybrid systems and the integration of advanced material science principles continue to expand the horizons of drug delivery technologies, promising more effective and safer therapeutic options for patients.

3. Significance of Study

The significance of transitioning from nanoparticles to biomaterials in drug delivery lies in several key advancements and potential improvements in therapeutic outcomes. Here's a breakdown of the importance and implications of this shift:

Enhanced Biocompatibility and Safety: Biomaterials are often designed to be highly biocompatible and biodegradable, which reduces the risk of toxicity compared to some types of nanoparticles. This shift can lead to safer drug delivery systems that are less likely to cause adverse immune reactions.

Targeted Drug Delivery: Both nanoparticles and biomaterials can be engineered to target specific tissues or cells. However, biomaterials can offer additional modalities for targeting and release, including environmental responsiveness and the ability to integrate with biological systems more seamlessly.

Controlled Release: Biomaterials can provide sophisticated mechanisms for the controlled release of drugs, including the ability to respond to environmental triggers such as pH, temperature, or enzymes. This can improve the therapeutic efficacy and reduce the frequency of dosage.

Regenerative Medicine: Biomaterials are particularly significant in the field of regenerative medicine. They can be designed to facilitate tissue repair and regeneration, not just serve as carriers for drugs. This dual function can be particularly beneficial in treatments requiring both therapeutic and regenerative capabilities.

Multifunctionality: Biomaterials can be engineered to perform multiple functions simultaneously. For example, they can be used to deliver drugs while also providing structural support to tissues or releasing growth factors to aid in healing processes.

Sustainability and Scalability: The production and degradation processes of biomaterials can be more environmentally sustainable than those of some synthetic nanoparticles. Additionally, advancements in biomaterial synthesis might offer scalable approaches conducive to large-scale production.

Innovation in Design: The shift to biomaterials opens new avenues for innovative drug delivery systems that integrate more closely with biological systems. This includes the development of smart biomaterials that can adapt their behavior in real time to changing physiological conditions.

Overall, transitioning from nanoparticles to biomaterials in drug delivery represents a move towards more sophisticated, safe, and patient-friendly approaches. It aligns with the broader goals of personalized medicine and could significantly improve the way many conditions are treated.

4. Proposed Methodology

The advancement of drug delivery from nanoparticles to biomaterials involves several key methodological steps, encompassing the design, synthesis, characterization, and application of biomaterials. Here is an outline of the typical methodology:

Step 1: Design and Selection of Biomaterials

Objective Identification: Define the specific therapeutic goals, such as targeting a particular tissue, controlling drug release rate, or reducing side effects.

Material Selection: Choose appropriate biomaterials based on biocompatibility, biodegradability, mechanical properties, and the ability to encapsulate and release the drug. Common biomaterials include natural polymers (e.g., alginate, chitosan), synthetic polymers (e.g., PLGA, PEG), and biohybrids.

Step 2. Synthesis and Fabrication

Polymerization and Cross-linking: Develop methods to synthesize the chosen biomaterials, often involving polymerization and cross-linking processes to achieve the desired mechanical and chemical properties.

Nano structuring: Fabricate the biomaterials into nanostructures such as nanoparticles, nanofibers, or hydrogels using techniques like electrospinning, self-assembly, or emulsion methods.

Step 3. Drug Encapsulation and Loading

Encapsulation Techniques: Employ techniques such as solvent evaporation, coacervation, or nanoprecipitation to encapsulate the drug within the biomaterial matrix.

Loading Efficiency: Optimize the drug loading efficiency to ensure adequate drug concentration within the biomaterial without compromising its structural integrity.

Step 4. Characterization

Physical and Chemical Characterization: Use techniques like scanning electron microscopy (SEM), transmission electron microscopy (TEM), Fourier-transform infrared spectroscopy (FTIR), and nuclear magnetic resonance (NMR) to characterize the physical and chemical properties of the biomaterials.

Drug Release Profiles: Evaluate the drug release profiles using in vitro release studies to determine the release kinetics and mechanisms (e.g., diffusion, degradation).

Step 5. Biocompatibility and Safety Testing

In Vitro Studies: Conduct cytotoxicity assays (e.g., MTT assay) on relevant cell lines to assess biocompatibility.

In Vivo Studies: Perform animal studies to evaluate the biodistribution, pharmacokinetics, and potential toxicity of the biomaterial-based drug delivery system.

Step 6. Targeting and Functionalization

Surface Modification: Modify the surface of biomaterials with targeting ligands (e.g., antibodies, peptides) to enhance specific tissue or cell targeting.

Stimuli-Responsive Features: Incorporate stimuli-responsive elements (e.g., pH-sensitive, temperature-sensitive) to enable controlled and site-specific drug release.

Step 7. Regulatory and Ethical Considerations

Regulatory Compliance: Ensure compliance with regulatory guidelines for biomaterials and drug delivery systems. This includes thorough documentation and submission to regulatory bodies such as the FDA or EMA.
Ethical Approval: Obtain ethical approval for in vivo and clinical studies, ensuring adherence to ethical standards in biomedical research.

Step 8: Clinical Translation

Clinical Trials: Conduct phased clinical trials to evaluate the safety and efficacy of the biomaterial-based drug delivery system in humans.

Scale-Up and Manufacturing: Develop scalable manufacturing processes to produce the biomaterial-based drug delivery systems in larger quantities while maintaining quality and consistency.

Step 9. Data Analysis and Optimization

Data Collection: Collect and analyze data from in vitro, in vivo, and clinical studies to assess performance and identify areas for improvement.

Iterative Optimization: Iterate the design and fabrication processes based on the collected data to optimize the drug delivery system for better performance and patient outcomes.

Step 10. Commercialization

Market Analysis: Conduct market analysis to identify potential applications and market segments for the biomaterial-based drug delivery system.

Intellectual Property: Secure patents and intellectual property rights to protect the innovations.
Partnerships and Licensing: Establish partnerships with pharmaceutical companies and pursue licensing opportunities to bring the technology to market.

By following this comprehensive methodology, researchers and developers can systematically advance drug delivery technologies from traditional nanoparticles to sophisticated biomaterials, potentially transforming therapeutic practices and improving patient outcomes.

5. Limitations and Future Implications

While transitioning from nanoparticles to biomaterials in drug delivery offers many potential benefits, there are also several limitations and challenges associated with this shift:

Complexity in Design and Manufacturing: Biomaterials often require intricate design and precise engineering, which can complicate the manufacturing process. Producing these materials at scale while maintaining consistency and quality can be challenging and expensive.

Regulatory Hurdles: Biomaterials used in drug delivery must meet stringent regulatory standards to ensure their safety and efficacy. The approval process for new biomaterials can be lengthy and complex, potentially delaying the availability of new treatments.

Stability Issues: Biomaterials may have stability issues, especially when exposed to various physiological conditions. Ensuring that these materials maintain their

integrity and functionality throughout the delivery process and within the body can be difficult.

Potential for Immune Reactions: Although biomaterials are designed to be biocompatible, there is still a risk of immune reactions or rejection by the body. Understanding and mitigating these responses require extensive research and testing.

Cost: Developing and producing biomaterials can be more expensive than traditional nanoparticles due to the complexity of their design and the materials used. This can increase the overall cost of drug delivery systems and make them less accessible.

Limited Understanding of Long-term Effects: The long-term effects of many new biomaterials are not yet fully understood. More research is needed to determine how these materials interact with the body over extended periods and what potential side effects may arise.

Scalability: While biomaterials offer many advantages, scaling up their production to meet commercial demand while maintaining quality and functionality is a significant challenge.

Technical Challenges: The development of biomaterials often involves overcoming technical challenges related to their synthesis, functionalization, and integration with therapeutic agents. These challenges can slow down the development process and limit the applicability of certain biomaterials.

Variability in Biological Environments: The effectiveness of biomaterials can vary depending on the specific biological environment in which they are used. Factors such as pH, enzymatic activity, and the presence of other biological molecules can influence the performance of biomaterials, making it difficult to predict their behavior in different patients or conditions.

Ethical and Environmental Concerns: The sourcing and disposal of certain biomaterials may raise ethical and environmental concerns. Ensuring that biomaterials are sourced sustainably and do not pose environmental hazards is an important consideration.

In summary, while the transition to biomaterials in drug delivery holds great promise, addressing these limitations and challenges is crucial for the successful development and implementation of these advanced therapeutic systems.

The transition from nanoparticles to biomaterials in drug delivery has several future implications that could significantly impact medicine, healthcare, and related fields. Here are some potential implications:

Personalized Medicine: Biomaterials can be engineered to cater to individual patient needs, paving the way for more personalized treatment plans. This could lead to higher efficacy and reduced side effects as treatments are tailored to the specific genetic and physiological characteristics of each patient.

Advancements in Regenerative Medicine: The integration of biomaterials in drug delivery systems could enhance regenerative medicine practices. Biomaterials can be used to deliver not only drugs but also cells and growth factors, promoting tissue repair and regeneration, and leading to new treatments for degenerative diseases and injuries.

Improved Chronic Disease Management: For chronic diseases that require long-term medication, biomaterials can provide more stable and controlled release mechanisms, improving patient compliance and overall management of conditions like diabetes, cardiovascular diseases, and arthritis.

Enhanced Cancer Treatments: Biomaterials can offer more precise targeting of cancer cells, minimizing damage to healthy tissue and reducing side effects. This could lead to more effective chemotherapy, radiotherapy, and immunotherapy treatments.

Development of Smart Drug Delivery Systems: The future could see the rise of smart drug delivery systems that can respond to specific stimuli (e.g., changes in pH, temperature, or specific biomarkers) to release drugs at the optimal time and place in the body. This could revolutionize the way drugs are administered and improve their therapeutic outcomes.

Interdisciplinary Collaborations: The development and application of biomaterials in drug delivery will likely spur collaborations across multiple disciplines, including materials science, bioengineering, chemistry, and medicine. This interdisciplinary approach could accelerate innovation and lead to breakthroughs in drug delivery technologies.

Reduced Environmental Impact: Biomaterials are often derived from natural sources or designed to be biodegradable, potentially reducing the environmental footprint of drug manufacturing and disposal. This shift could promote more sustainable practices in the pharmaceutical industry.

Novel Therapeutic Applications: The unique properties of biomaterials may open up new therapeutic applications that are not possible with traditional nanoparticles. For example, biomaterials could be used to create advanced wound dressings that deliver drugs and promote healing or develop implants that release therapeutic agents over long periods.

Economic Impact: The advancement of biomaterial-based drug delivery systems could lead to new markets and economic growth within the pharmaceutical and biotechnology industries. Companies that invest in this technology may gain a competitive edge, driving further research and development.

Ethical and Policy Considerations: As biomaterials become more prevalent, there will be a need for updated ethical guidelines and regulatory policies to address issues related to safety, efficacy, and long-term impact. Policymakers and ethicists will need to work together to

ensure that these technologies are developed and deployed responsibly.

In summary, the future implications of transitioning from nanoparticles to biomaterials in drug delivery are vast and multifaceted, with the potential to significantly advance medical treatments, improve patient outcomes, and drive innovation across multiple fields. However, realizing these implications will require ongoing research, collaboration, and careful consideration of ethical and regulatory challenges.

6. Expected Outcome

It is anticipated that the use of biomaterials in place of nanoparticles for drug administration would result in better therapies, fewer adverse effects, more patient compliance, enhanced regenerative medicine, smart drug delivery systems, innovative therapeutic modalities, sustainability, and environmental advantages. Therapeutic agents may be delivered at the appropriate time and location in the body with the help of biomaterials, which can improve drug delivery's accuracy and control. They may also increase patient safety and lower the chance of adverse consequences. Intelligent medication delivery systems provide dynamic treatment choices by reacting to certain physiological stimuli. Personalized medicine may be developed with the use of biomaterials, spurring innovation and economic growth in the biotechnology and pharmaceutical sectors. Additionally, by offering a steady and regulated medication delivery, they may enhance the treatment of chronic diseases. To guarantee the safe and responsible research and implementation of novel medicines, breakthroughs in ethics and regulations will be required.

References

[1] Augst, A. D., Kong, H. J., & Mooney, D. J. (2006). Alginate hydrogels as biomaterials. Macromolecular Bioscience, 6(8), 623-633.
[2] Bae, H., Ahari, A. F., Warren, H., Jang, S., & Park, K. (2011). Responsive hydrogels for drug delivery. Advanced Drug Delivery Reviews, 63(7), 626-639.
[3] Cheng, Y., Xu, Z., Ma, M., Xu, T. (2008). Dendrimers as drug carriers: Applications in different routes of drug administration. Journal of Pharmaceutical Sciences, 97(1), 123-143.
[4] Chithrani, B. D., Ghazani, A. A., & Chan, W. C. W. (2006). Determining the size and shape dependence of gold nanoparticle uptake into mammalian cells. Nano Letters, 6(4), 662-668.
[5] Dobrovolskaia, M. A., McNeil, S. E. (2008). Immunological properties of engineered nanomaterials. Nature Nanotechnology, 3(3), 134-139.
[6] Duncan, R., & Gaspar, R. (2011). Nanomedicine(s) under the microscope. Molecular Pharmaceutics, 8(6), 2101-2141.
[7] Farokhzad, O. C., & Langer, R. (2009). Impact of nanotechnology on drug delivery. ACS Nano, 3(1), 16-20.
[8] Ge, Z., & Liu, S. (2009). Functional block copolymer assemblies responsive to tumor and intracellular microenvironments for site-specific drug delivery and enhanced imaging performance. Chemical Society Reviews, 38(5), 1381-1394.
[9] Hrkach, J., von Hoff, D., Ali, M. M., Andrianova, E., Auer, J., Campbell, T., & Zale, S. (2012). Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Science Translational Medicine, 4(128), 128ra39.
[10] Hubbell, J. A. (1995). Biomaterials in tissue engineering. Nature Biotechnology, 13(6), 565-576.
[11] Illum, L. (1998). Chitosan and its use as a pharmaceutical excipient. Pharmaceutical Research, 15(9), 1326-1331.
[12] Kamaly, N., Yameen, B., Wu, J., & Farokhzad, O. C. (2016). Degradable controlled-release polymers and polymeric nanoparticles: Mechanisms of release. Chemical Reviews, 116(4), 2602-2663.
[13] Kesharwani, P., Jain, K., & Jain, N. K. (2014). Dendrimer as nanocarrier for drug delivery. Progress in Polymer Science, 39(2), 268-307.
[14] Kost, J., & Langer, R. (2012). Responsive polymeric delivery systems. Advanced Drug Delivery Reviews, 64(4), 327-341.
[15] Kumar, M. N. V. R., Muzzarelli, R. A. A., Muzzarelli, C., Sashiwa, H., & Domb, A. J. (2004). Chitosan chemistry and pharmaceutical perspectives. Chemical Reviews, 104(12), 6017-6084.
[16] Kumari, A., Yadav, S. K., & Yadav, S. C. (2010). Biodegradable polymeric nanoparticles based drug delivery systems. Colloids and Surfaces B: Biointerfaces, 75(1), 1-18.
[17] Langer, R., & Peppas, N. A. (2003). Advances in biomaterials, drug delivery, and bio nanotechnology. AIChE Journal, 49(12), 2990-3006.
[18] Langer, R., & Tirrell, D. A. (2004). Designing materials for biology and medicine. Nature, 428(6982), 487-492.
[19] Lee, K. Y., & Mooney, D. J. (2012). Alginate: Properties and biomedical applications. Progress in Polymer Science, 37(1), 106-126.
[20] Lee, S. B., Ha, D. I., & Son, J. H. (2003). Biocompatibility and biodegradation of cellulose materials. Journal of Biomedical Materials Research, 66(3), 567-574.
[21] Li, J., & Mooney, D. J. (2016). Designing hydrogels for controlled drug delivery. Nature Reviews Materials, 1(12), 16071.
[22] Maeda, H. (2001). The enhanced permeability and retention (EPR) effect in tumor vasculature: The key role of tumor-selective macromolecular drug targeting. Advances in Enzyme Regulation, 41, 189-207.
[23] Mao, S., Shuai, X., Unger, F., Simon, M., Bi, D., & Kissel, T. (2004). The depolymerization of chitosan: Effects on physicochemical and biological properties. International Journal of Pharmaceutics, 281(1-2), 45-54.
[24] Majoros, I. J., Myc, A., Thomas, T., Mehta, C. B., & Baker, J. R. (2008). PAMAM dendrimer-based multifunctional conjugate for cancer therapy:

Synthesis, characterization, and functionality. Bioconjugate Chemistry, 17(3), 319-326.
[25] Menjoge, A. R., Kannan, R. M., & Tomalia, D. A. (2010). Dendrimer-based drug and imaging conjugates: Design considerations for nanomedical applications. Drug Discovery Today, 15(5-6), 171-185.
[26] Nguyen, K. T., & West, J. L. (2002). Photopolymerizable hydrogels for tissue engineering applications. Biomaterials, 23(22), 4307-4314.
[27] Oberdörster, G., Oberdörster, E., & Oberdörster, J. (2005). Nanotoxicology: An emerging discipline evolving from studies of ultrafine particles. Environmental Health Perspectives, 113(7), 823-839.
[28] Peppas, N. A., Hilt, J. Z., Khademhosseini, A., & Langer, R. (2006). Hydrogels in biology and medicine: From molecular principles to bio nanotechnology. Advanced Materials, 18(11), 1345-1360.
[29] Raghupathi, K., Liu, Y., & Turner, J. R. (2017). Assembly of responsive polymer composites for biomedical applications. Biomacromolecules, 18(5), 1316-1330.
[30] Sahoo, D., Kumar, M. N. V. R., & Sahoo, S. K. (2009). Biodegradable polymers: Biomedical applications. International Journal of Pharmaceutics, 338(1-2), 1-7.
[31] Siepmann, J., & Göpferich, A. (2001). Mathematical modeling of bioerodible, polymeric drug delivery systems. Advanced Drug Delivery Reviews, 48(2-3), 229-247.
[32] Soni, K. S., Desale, S. S., & Bronich, T. K. (2016). Nanogels: An overview of properties, biomedical applications and obstacles to clinical translation. Journal of Controlled Release, 240, 109-126.
[33] Veiseh, O., Tang, B. C., Whitehead, K. A., Anderson, D. G., & Langer, R. (2015). Managing toxicity of biomaterials for medical devices and drug delivery systems. Nature Reviews Drug Discovery, 14(1), 45-57.
[34] Zhan, C., Gu, B., Xie, C., Li, J., & Liu, Y. (2011). Nanoparticle-embedded hydrogels as thermal-sensitive drug delivery systems. International Journal of Pharmaceutics, 414(1-2), 271-279.